Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct 22;30(1):1008.
doi: 10.1186/s40001-025-03279-8.

Novel inflammation biomarkers in adult minimal change disease: predicting steroid-resistance and relapse

Weiwei Zhang  1 , Wei Lin  2 , Huipeng Ge  1 , Wenbin Tang  3 , Zhangzhe Peng  1   4 , Qiongjing Yuan  5   6   7   8 , Xiangcheng Xiao  9   10
Affiliations

Novel inflammation biomarkers in adult minimal change disease: predicting steroid-resistance and relapse

Weiwei Zhang et al. Eur J Med Res. .

Abstract

Introduction: The novel systemic inflammation markers are a class of indicators combining clinically common laboratory indices, reflecting the underlying immune and inflammatory status. Minimal change disease (MCD) is an important cause of idiopathic nephrotic syndrome (INS) in adults. Novel systemic inflammation markers were evaluated for their ability to predict treatment response to steroids and subsequent relapse in adult-onset MCD.

Methods: This unicentric, retrospective study included the clinical data of adult-onset INS patients who were pathologically diagnosed with MCD at Xiangya Hospital of Central South University from January 2010 to December 2021 and followed up with the patients' remission after adequate steroid treatment, starting from the time of initial complete remission to May 31, 2022, with recurrence as the end-point event. Eight common and associated novel systemic inflammation markers were collected, and univariate analysis of these markers was performed using dummy variable assignment or maximally selected rank statistics. Multivariate logistic regression and Cox regression statistics identified the independent risk factors for steroid resistance and relapse after initial remission in adult-onset MCD, respectively.

Results: A total of 121 patients were included; the median age was 22 (19,40) years, and there were 92 (76%) men. Adequate corticosteroids were the initial treatment: 98 (81%) patients achieved remission, and 23 (19%) developed steroid resistance. Of the 98 patients with remission, the median age was 25 (19, 44) years, 76 (77.6%) were male, the median follow-up time was 11.4 (6.3, 33.4) months, and 46 (46.9%) experienced relapse. The multivariate analysis showed that elevated C-reactive protein to albumin ratio (CAR) (≥ 0.196) and derived neutrophil/ (leukocyte minus neutrophil) ratio (dNLR) (≥ 1.32) were independent predictors of steroid resistance and relapse in adult-onset MCD, respectively.

Conclusions: The novel systemic inflammation markers CAR and dNLR may play significant roles in steroid treatment and the prognosis of MCD in adults, and deeper clinical studies in the future are warranted.

Keywords: Independent risk factor; Minimal change disease; Novel systemic inflammation markers; Relapse; Steroid resistance.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: This retrospective study was approved by the institutional review board of Xiangya Hospital of Central South University, and the requirement for informed consent was waived. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Summary of the clinical course of the study population
Fig. 2
Fig. 2
The standardized log-rank statistics and estimated cut-off point for dNLR (cutpoint: 1.32)
Fig. 3
Fig. 3
Kaplan–Meier curves of the two groups of MCD remission patients separated by dNLR cut-off point of 1.32 (p = 0.032)
Fig. 4
Fig. 4
TimeROC curves of the Cox proportional hazards model
See this image and copyright information in PMC

References

    1. Beck L, Bomback AS, Choi MJ, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis. Am J Kidney Dis. 2013;62(3):403–41. - PubMed
    1. Floege J, Amann K. Primary glomerulonephritides. Lancet. 2016;387(10032):2036–48. - PubMed
    1. Rovin BH, Caster DJ, Cattran DC, et al. Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. Kidney Int. 2019;95(2):281–95. - PubMed
    1. Kidney Disease: Improving Global Outcomes Glomerular Diseases Work G. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4S):S1–276. - PubMed
    1. Rivera HF. How to treat corticosteroid-resistant idiopathic focal segmental glomerulosclerosis? Nefrologia. 2011;31(3):247–50. - PubMed